"This session will provide a forum where biotechnology health economics, pricing and reimbursement professionals can discuss how to best establish the value of innovation while ensuring access to innovative biotech medicines. Participants will leave this session with best practices, new ideas and motivation to fuel debates with policymakers, payers and providers that will help shape sound health economic policy.

The audience should take home tools to help their company or organization manage the new policy or policies that come from thinking products of higher volume or higher cost require a higher standard of "evidence" or value to be covered or paid for."

Objective1:Discuss how we can best demonstrate the value of innovation and ensure access to innovative medicines and diagnostics.

Objective2:Share best practices for measuring value, including economic and patient-reported outcomes.

Objective3:Learn how to prepare a product for reimbursement or coverage under the challenges of aligning value and access.